期刊文献+

来氟米特对糖尿病肾病大鼠RANTES与FOXP3表达的影响 被引量:5

Influence of leflunomide on the expression of RANTES,FOXP3 and ED-1 in diabetic nephropathy rats
原文传递
导出
摘要 目的:观察RANTES、FOXP3、ED-1在肾组织中的蛋白表达,探讨LEF对糖尿病肾病肾组织炎症反应及病理改变的影响。方法:35只雄性Wistar大鼠随机分为正常对照组N(n=10)、模型DN(n=13)、来氟米特组DD(n=12)。采用弗氏完全佐剂(CFA)和链脲佐菌素(STZ)制备糖尿病肾病模型。检测24 h尿蛋白定量,HE染色观察肾脏组织学改变,免疫组织化学方法检测肾组织RANTES、FOXP3、ED-1表达。结果:与对照组比较,模型组24 h尿蛋白排泄量显著上升(P<0.05),模型组大鼠肾组织肾小球肥大、肾小管上皮细胞变性或脱落、单核/巨噬细胞浸润、肾间质病变等病理变化明显;模型组大鼠肾组织内RANTES、FOXP3、ED-1表达均明显增强(P<0.05);与模型组比较,LEF治疗组大鼠24 h尿蛋白下降,肾组织RAN-TES、FOXP3、ED-1表达显著减少,肾脏病理改变有所减轻。结论:LEF可能是通过抑制RANETS、FOXP3、ED-1在肾组织中的表达,减少炎症细胞在肾组织中的浸润,对延缓糖尿病肾病的发展具有一定的作用。 OBJECTIVE To observe the expression of RANTES, FOXP3, ED-1 protein expression in the kidney of diabetic nephropathy rats,and study the effects of leflunomide (LEF) intertention on inflammatory response and pathological changes. METHODS 35 male Wistar rats were randomly divided into normal control group N (n = 10), model group DN (n = 13), le flunomide group DD (n = 12). Rat model of diabetic nephropathy was induced by Freund's complete adjuvant (CFA) and streptozotocin (STZ). 24 h urinary protein was determined. Histological changes in renal tissue were observed by hematoxlin eosin (HE) staining. RANTES, FOXP3 and ED-1 protein expression in renal tissue were detected by immunohistochemistry. RESULTS Compared with control group,24 h urinary protein excretion increased significantly (P〈0. 05) in model group, rats kidney in model group showed glomerular hypertrophy, tubular epithelial cell degeneration or loss, monocyte / macrophage infiltration, renal interstitial disease and other pathological changes significantly, RANTES, FOXP3, ED1 expressions in renal tissues of model group were significantly increased (P〈0. 05);Compared with model group, 24 h urine protein and RANTES, FOXP3,ED-1 expressions and pathological changes in LEFtreated group were significantly reduced. CONCLUSION LEF probably inhibits RANETS,FOXP3, ED-1 expression and reduced inflammatory cell infiltration in renal tissues. LEF plays a certain role in delaying the development of diabetic nephropathy.
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2012年第9期667-671,共5页 Chinese Journal of Hospital Pharmacy
基金 贵州省科技厅基金资助[编号:黔科合J字2008(2003号)]
关键词 糖尿病肾病 来氟米特 FOXP3 RANTES ED-1 diabetic nephropathy leflunomide FOXP3 RANTES ED-1
  • 相关文献

参考文献8

  • 1Fontenot JD,Rudensky AY. A well adapted regulatory contrivance:regulatory T cell development and the forkhead family transcription factor Foxp3[J].Nature Immunology,2007.331-337.
  • 2Brey MD,Bottinger E,Brosius FC 3rd. Mouse models of diabetic nephropathy[J].Journal of the American Society of Nephrology,2005.27-45.
  • 3梁春联,王静.免疫调节剂对1型糖尿病大鼠Foxp3表达的影响[J].青岛大学医学院学报,2008,44(1):24-26. 被引量:3
  • 4Phillips AO,Steadman R. Diabetic nephropathy:the central role of renal proximal tubular cells in tubulointerstitial injury[J].Histology and Histopathology,2002,(01):247-252.
  • 5Bohle A,Maekensen-Haen S,Gise HV. Significance of tubulointerstitial changes in the renal cortex for the excretory function and concentration ability of the kidney:a morohometric contribution[J].Ann J Nephrol,1987.421-443.
  • 6Bettelli E,Dastrange M,Oukka M. Foxp3 interacts with nuclear factor of activated T cells and NF-kappa B to repress cytokine gene expression and effector functions of T helper cells[J].Proceedings of the National Academy of Sciences(USA),2005.5138.
  • 7Wang Z,Larregina AT,Shufesky WJ. Use of the inhibitory effect of apoptotic cells on dendritic cells for graft survival via T-cell deletion and regulatory T cell[J].Journal of Immunology,2006,(09):5293-5298.
  • 8曹励欧,倪兆慧,钱家麒,林爱武,张伟明,方炜,朱铭力,王琴,牟姗,严玉澄.来氟米特对Ⅳ型及Ⅴ型狼疮肾炎的诱导维持治疗[J].中华肾脏病杂志,2007,23(1):3-7. 被引量:20

二级参考文献18

共引文献21

同被引文献51

  • 1Neeraj Kumar Agrawal,Saket Kant.Targeting inflammation in diabetes: Newer therapeutic options[J].World Journal of Diabetes,2014,5(5):697-710. 被引量:42
  • 2王剑青,邓安国,戴勇.维持性血液透析患者微炎症状态相关因子的变化[J].临床内科杂志,2005,22(7):451-454. 被引量:30
  • 3付宇,王丹,石鹏,赵武,林为民,袁莉.来氟米特治疗糖尿病肾病大量蛋白尿20例临床分析[J].临床内科杂志,2007,24(7):470-471. 被引量:14
  • 4Nelson RG, Tuttle KR. The new KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and CKD[ J]. Blood Pu- rif,2007,25 ( 1 ) : 112-114.
  • 5Frolich M,hnhof A,Berg G, etal. A ssoeiation between C-reactive pro- tein and features of the metabolic synd rome[ J]. Diabetes Care, 2000, 23 (12) : 1835-1839.
  • 6Grisar J, Aringer M, K611er MD, et al. Leflunomide reduces transendothe- lial migration of peripheral blood mononuclearceus [ J ]. Ann Rheum Dis, 2004,63 ( 12 ) : 1632-1637.
  • 7Phillips AO, Steadman R. Diabetic nephropathy: the central role of renal proximal tubular cells in tubulointerslitial injury [ J ]. Histol Histopatho1,2002,17 ( 1 ) :247-252.
  • 8Gluhovschi GH, Gluhovschi C, Vlad A, et al. Diabetic nephropathy and multiorga protection. Part [ J ]. Rom J InternMed,2011,49(3):163-177.
  • 9Gluhovsehi GH, Gluhovsehi C, Vlad A, et al. Diabetic nephropathy and multiorgan protection Part [ J]. RomJ Intem Med,2011,49(4): 237-249.
  • 10Li L, Zhao YW, Zeng JS, et al. Rituximab regulates the expression of the Raf kinase inhibitor protein via NF-kappaB in renal tissue of rats with diabetic nephropathy[ J ]. Genet Mol Res, 2013,12(3) :2973-2981.

引证文献5

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部